Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Injectable Drug Delivery Market Forecast: USD 1,034.78 Billion by 2030 – MarketsandMarkets™

globenewswire.com
JNJ Johnson & Johnson Services, Inc. is listed as a top company in the injectable drug delivery formulations market, indicating its significant presence and involvement in this growing sector. PFE Pfizer Inc. is identified as a leading company in the injectable drug delivery formulations market, highlighting its role in the development and supply of these critical medical products. MRK Merck & Co., Inc. is recognized as a key player in the injectable drug delivery formulations market, suggesting its active participation and contribution to the industry's growth. CAH Cardinal Health is a leading company in the injectable drug delivery devices segment, focusing on data analytics, AI, and strategic partnerships, indicating a forward-looking approach. BDX BD maintains a strong presence in the injectable drug delivery devices market through its extensive portfolio and strategic partnerships, positioning it as a significant contributor. BAX Baxter is strengthening its position in the injectable drug delivery devices market through strategic alliances and acquisitions, indicating active growth and expansion efforts.

Injectable Drug Delivery Market Forecast: USD 1,034.78 Billion by 2030 – MarketsandMarkets™ Delray Beach, FL, Sept. 07, 2026 (GLOBE NEWSWIRE) -- MarketsandMarkets™ projects the global injectable drug delivery market will grow from USD 690.23 billion in 2025 to USD 1,034.78 billion by 2030, at a CAGR of 8.4% during the forecast period. Market growth is fueled by the rising prevalence of chronic diseases such as diabetes, cancer, cardiovascular diseases, and autoimmune disorders, increasing demand for biologics, advancements in injectable formulations, and the growing adoption of patient-friendly drug delivery devices including prefilled syringes, autoinjectors, pen injectors, wearable injectors, and needle-free systems.

Get PDF Brochure - Market Data & Segmentation: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=150

Key Market Highlights

Why This Market Matters

The injectable drug delivery market is expanding as the global burden of chronic diseases continues to rise and demand for biologics increases. Injectable administration provides high bioavailability, rapid onset of action, and precise drug delivery, making it an important route for the treatment of cancer, diabetes, cardiovascular diseases, autoimmune disorders, and other chronic and infectious diseases. The growing adoption of self-administration technologies is also improving patient autonomy and compliance, while increasing healthcare access in emerging markets such as India, Brazil, and China is supporting market expansion.

Market Overview

The injectable drug delivery market is witnessing sustained growth as pharmaceutical and medical device companies develop advanced delivery technologies to address the increasing demand for biologics and chronic disease therapies. The market includes injectable drug delivery devices and formulations, with innovations ranging from nanoparticles, microparticles, and liposomes to prefilled syringes, cartridges, autoinjectors, pen injectors, wearable injectors, and needle-free systems. The increasing focus on personalized medicine, combination therapies, home-based care, and patient-friendly administration is further supporting market development.

Analyst Perspective

The injectable drug delivery industry is moving toward more convenient, connected, and patient-centric delivery solutions. Smart injectors with connectivity and adherence monitoring, large-volume subcutaneous delivery systems, microneedles, needle-free injectors, and wearable delivery technologies are creating new opportunities for manufacturers. Partnerships between pharmaceutical companies and device developers are also accelerating the development of biologics-compatible drug delivery platforms. At the same time, companies are increasingly exploring sustainable and reusable injection systems to address environmental requirements.

Speak to Our Analyst - Get Custom Insights: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=150

Segment Analysis

By product, the formulations segment accounted for the largest share of the injectable drug delivery market in 2024. The dominance of this segment is driven by the increasing use of biologics and biosimilars, which require parenteral administration for efficacy and stability. Rising incidence of chronic and infectious diseases, particularly oncology, diabetes, autoimmune disorders, and hormonal conditions, is further increasing demand for high-potency and fast-acting injectable formulations. The growing use of monoclonal antibodies, insulin analogs, and long-acting injectables is also supporting segment growth.

By therapeutic application, the autoimmune diseases segment accounted for the largest market share in 2024. The chronic nature of autoimmune disorders such as rheumatoid arthritis, multiple sclerosis, and Crohn’s disease and the widespread use of biologics requiring parenteral administration are key factors supporting segment growth. Increasing adoption of autoinjectors and pen injectors is enabling more convenient at-home administration, while regulatory approvals for biosimilars and novel monoclonal antibodies are expanding treatment options.

By end user, the hospitals & clinics segment accounted for the largest share of the market in 2024. This dominance is attributed to the high volume of inpatient and outpatient procedures requiring rapid and controlled drug administration. Hospitals and clinics provide the infrastructure required for complex therapies such as chemotherapy, biologics, and critical care drugs. Increasing adoption of smart injectors, closed-system drug transfer devices, prefilled syringes, and long-acting injectables is further supporting the segment.

Regional Analysis

North America dominated the injectable drug delivery market in 2024. The region's leading position is supported by a high burden of chronic diseases such as diabetes, cancer, and rheumatoid arthritis, well-established healthcare infrastructure, early adoption of biologics, and strong reimbursement policies. The US also has a robust regulatory framework and a high concentration of pharmaceutical and biotechnology companies investing in advanced injectable therapies.

The growing demand for self-administration devices and home-based care is further supporting regional market growth. Autoinjectors, wearable injectors, and needle-free systems are gaining adoption due to their user-friendly designs and reduced dependence on clinical settings. Connected injectable systems, biosimilars, large-volume subcutaneous delivery devices, and strategic collaborations between pharmaceutical and device manufacturers are also shaping the North American market.

Key Industry Trends

Competitive Landscape

The competitive landscape of the injectable drug delivery market is led by established pharmaceutical, biotechnology, medical device, and healthcare companies including Johnson & Johnson Services, Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), Pfizer Inc. (US), Merck & Co., Inc. (US), Novartis AG (Switzerland), Cardinal Health (US), BD (US), B. Braun SE (Germany), Baxter (US), and Terumo Corporation (Japan).

The injectable drug delivery market is categorized into devices and formulations. The top five companies in the injectable drug delivery devices segment are Cardinal Health, BD, Baxter, B. Braun SE, and Terumo Corporation. Cardinal Health is focusing on data analytics, artificial intelligence, predictive modeling, innovation, and strategic partnerships. BD maintains a strong presence through its extensive portfolio of medical devices, diagnostics, and bioscience solutions, as well as strategic partnerships. Baxter is strengthening its position through strategic alliances and acquisitions, while B. Braun SE is expanding its manufacturing capabilities and pursuing strategic acquisitions. Terumo Corporation is benefiting from growth in markets such as India and China and investments in ePRISM technology.

The top five companies in the injectable drug delivery formulations market are Johnson & Johnson Services, Inc., F. Hoffmann-La Roche Ltd., Pfizer Inc., Merck & Co., Inc., and Novartis AG. These companies are strengthening their market positions through portfolio expansion, strategic partnerships and acquisitions, product and technology innovation, and continued investment in research and development.

Related Reports

US Injectable Drug Delivery Market

UK Injectable Drug Delivery Market